Despite its enduring relevance as the single most effective and important evidence-based
treatment for schizophrenia, underutilization of clozapine remains considerable. To a …

Elevated brain glutamate has been implicated in non-response to antipsychotic medication
in schizophrenia. Biomarkers that can accurately predict antipsychotic non-response from …

Objective Clozapine response varies widely from person to person, which may be due to
inter-individual genetic variability. This umbrella review aims to summarize the current …

Clozapine is the gold standard for treating treatment-resistant schizophrenia although
continuously underutilized. Previous surveys of clinicians have found that some of the most …

Given evidence pointing toward a role for immune dysregulation in the pathogenesis of
schizophrenia, anti-inflammatory agents are promising adjunctive treatments that have …

Background Clozapine is an antipsychotic drug with unique efficacy, and it is the only
recommended treatment for treatment-resistant schizophrenia (TRS: failure to respond to at …

Introduction Little is known about predictors of clinical response to clozapine treatment in
treatment-resistant psychosis. Most published cohorts are small, providing inconsistent …

Background: A proportion of people with treatment-resistant schizophrenia fail to show
improvement on clozapine treatment. Knowledge of the sociodemographic and clinical …

Both the underutilization of clozapine and treatment resistance of patients to clozapine are
serious problems worldwide. Identifying clinical markers predicting response to clozapine …

Worldwide efforts to promote greater lithium use for mood disorders have increased the
need for evidence-based guidance addressing key questions related to initiation, monitoring …